









Markets
/
Stocks
/
nasdaq-incr
/

InterCure Ltd

INCR



View Detailed Chart

1.460USD

-0.030-2.05%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

66.54MMarket Cap

3.18P/E TTM



InterCure Ltd

1.460

-0.030-2.05%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-2.05%

5 Days

-7.01%

1 Month

-10.98%

6 Months

-5.90%

Year to Date

-8.18%

1 Year

-21.51%

View Detailed Chart

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a good stock market performance, the company shows weak fundamentals and technicals, which don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

63 / 72

Overall Ranking

508 / 4720

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Overvalued

The company’s latest PE is -1.07, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 16.78M shares, increasing 6.02% quarter-over-quarter.